First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

By B. Solomon, T. Mok, Dong-Wan Kim, Yi-long Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari and 5 more. New England Journal of Medicine, 2014

3,013 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/733a3a91885146e0d9e5a6f1767f470b0b6c7ea1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. C. Zappa
2. Shaker A. Mousa
3. K. Kerr
4. M. Hellmann

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “001) and higher ORR with crizotinib compared with ChT [199].”
• Non-small cell lung cancer: current treatment and future advances. (2016, background): “Overall crizotinib showed significant improvements in progression-free survival and overall response rate compared with standard chemotherapy and its safety profile was acceptable (64).”
• Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer (2018, neutral): “Pain in extremity 6 (4) 0 17 (12) 1 (1)”
• Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1) (2017, neutral): “Arthralgia 12 (10) 6 (5) 1 (1) 19 (16)”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “60) Improved 4 [82]”
• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017, background): “Mixed with predominantly adenocarcinoma component 1 (1) 0”
• Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer (2016, neutral): “Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.”